Australia's Island Pharmaceuticals surges 47% after galidesivir wins emergency-use approval for Bundibugyo Ebola strain in Uganda
Australia's Island Pharmaceuticals surged as much as 47% after announcing its experimental antiviral galidesivir secured regulatory and ethics approvals for emergency use in patients with the Bundibugyo strain of Ebola in Uganda.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near Uganda
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Briefings
More story pages
Kailera's obesity drug meets main goal of late-stage trials in China, Reuters reports. The successful trial result marks a key milestone for the company's weight-loss treatment program.
Kailera's obesity drug meets main goal of late-stage trials in China
South Africa prepares for possible Ebola outbreak as virus spreads in Democratic Republic of Congo, raising concerns Africa's busiest travel hubs could import cases.
South Africa is preparing for a possible Ebola outbreak as the virus continues to spread in the Democratic Republic of Congo, raising concerns that the continent's busiest travel hubs may eventually import cases.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.